Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... intraocular inflammation can occur unilaterally after same-day bilateral injections of bevacizumab. RETINA 29:1213-1217, 2009." Lima and colleagues published their study in ...
2009 NOV 23 ... a study "To evaluate the visual and growth factor changes of two different intravitreal bevacizumab dosages for neovascular age-related macular degeneration. Fifty eyes of 50 patients with ...
2009 NOV 16 ... correlates with progressive tumor growth and poor outcomes in many types of cancer. Bevacizumab inhibits VEGF to promote regression of tumor vessels by limiting blood supply and tumor ...
2009 NOV 23 ... a study "To compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naive neovascular ...
2009 NOV 16 ... inhibit neovascularization may influence epithelial wound healing. Here, the effects of bevacizumab on corneal epithelial wound healing time in rabbit models, cell proliferation, and ...
2009 NOV 16 ... Ltd., including the right to receive 60% of the royalties from sales of Avastin=AE (Bevacizumab), Herceptin=AE (Trastuzumab), Lucentis=AE (Ranibizumab) and Xolair=AE (Omalizumab) and ...
2009 NOV 9 ... Ltd., including the right to receive 60% of the royalties from sales of Avastin=AE (Bevacizumab), Herceptin=AE (Trastuzumab), Lucentis=AE (Ranibizumab) and Xolair=AE (Omalizumab) and ...
2009 NOV 16 ... According to a study from the United States, "Bevacizumab is an antibody against vascular endothelial growth factor; sunitinib is an inhibitor of ...
2009 NOV 23 ... of signaling through VEGF has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Our goal was to discover an orally available, selective ...
2009 NOV 16 ... New research, 'Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the ...
2009 NOV 23 ... "The aim of this study was to assess the 12-month efficacy of intravitreal bevacizumab (IVB) injection for occult choroidal neovascularization secondary to age-related macular ...
2009 NOV 23 ... Japan conducted a study "To evaluate the 12-month follow-up results of intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion and to identify the ...
2009 NOV 16 ... researchers in Kagawa, Japan conducted a study "To investigate the pharmacokinetics of bevacizumab in rabbits for three different routes of administrations: intravitreal injection, ...
2009 NOV 23 ... with DNA-repair-deficient tumors," Dr. Murphy said. Keywords: Avastin, Bevacizumab, Biotechnology, Breast Cancer, Breast Carcinoma, Chemotherapy, Drug Development, Drug ...
2009 NOV 23 ... Turkey conducted a study "To evaluate the effects of repeated 1.25-mg intravitreal bevacizumab injections on cornea and uveoretinal tissues using histologic and biochemical analyses. ...
2009 NOV 16 ... and tumor growth of HCC. This anti-angiogenic effect is more effective than that of bevacizumab, which specifically targets vascular endothelial growth factor (VEGF). We found that the ...
2009 NOV 16 ... a study "To evaluate the ocular complications of intravitreal injection of high dose bevacizumab in monkey eyes. Four healthy monkeys (Macaca fuscata) received an intravitreal injection ...
2009 NOV 9 ... researchers in Balgat, Turkey conducted a study "To investigate the effect of bevacizumab in an experimental rabbit model of corneal neovascularization. The right eyes of 24 ...
2009 NOV 9 ... validate VEGF as a target in the treatment of clear cell RCC was the monoclonal antibody bevacizumab. Since then, anti-VEGF receptor therapy with multitargeted kinase inhibitors also has ...
